Division of Hematology and Oncology

October 27, 2022

Study reveals pathways for aggressive prostate cancer subtype

Research from Vanderbilt-Ingram Cancer Center has revealed new information about the molecular pathways of cribriform prostate cancer.

By Tom Wilemon
September 29, 2022

New Clinician Spotlight: Muhamed Baljević

Specializing in myeloma, amyloidosis and other plasma cell disorders, hematologist and medical oncologist Muhamed Baljević, MD, recently joined Vanderbilt University Medical Center.

By VUMC News and Communications
September 29, 2022

Policy, resources crucial for lung cancer screening: study

Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.

By Leigh MacMillan
September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

By Tom Wilemon
August 29, 2022

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

By Leigh MacMillan
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

By Tom Wilemon
August 17, 2022

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
By Tom Wilemon
August 11, 2022

Cell-free breast cancer “biopsy”

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
By Sarah E. Glass
August 2, 2022

Targeted cancer drug during pregnancy

The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
By Leigh MacMillan
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
By Tom Wilemon
June 16, 2022

Breast cancer biomarkers of response

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.
By Joshua Baker
May 26, 2022

Conquer Cancer awards given to five hematology-oncology fellows

Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.
By Tom Wilemon
May 6, 2022

Janet Darnell received a lifesaving lung transplant. Five months later she received lifesaving surgery for colon cancer. She calls herself a “walking miracle.”

Without the lung transplant, the cancer may never have been detected.
By Matt Batcheldor
1 2 3 4 5 6 … 15